MetaCap

Ocugen Inc. (OCGN)

NASDAQ: OCGNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.7679+0.0351 (+4.79%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

OCGN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$260.55M
EPS (TTM)
-$0.20
52-week range
0.691 – 2.73
Day range
0.71 – 0.8198
Volume / Avg
6.19M / 7.34M
Beta
—

52-week range

$0.691$2.73

OCGN stock today

Shares of Ocugen (OCGN) finished higher on Nov 20 at $0.7679, a gain of 4.79% or $0.0351 per share, versus the S&P 500's 3.70% decline. Shares are 71.8% below their 52-week high of $2.73, set on Mar 17, 2026 and 11.1% above the 52-week low of $0.691, near the bottom of the past year's range. OCGN is down 43.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 33.8%.

Ocugen has posted a net loss over the last twelve months (EPS of -$0.20), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Ocugen

Company profile

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Shankar Musunuri M.B.A., Ph.D.
Headquarters
Malvern, PA
Employees
116
IPO year
2014
Website
ocugen.com

Financial highlights

Full financials

In fiscal 2025, Ocugen generated $4.4 million in revenue, up 8.8% from fiscal 2024. Ocugen reported a net loss of $67.8 million, compared with a loss of $54.1 million a year earlier. Operating margin was -1425.7%.

Ocugen annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$4.41M$4.05M$6.04M$2.49M$0
Growth+8.83%-32.82%+142.60%—-100.00%
Net income$-67.85M$-54.05M$-63.08M$-86.80M$-58.37M
EPS (diluted)——$-0.26$-0.40$-0.30

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$12.17+1484.84%

  • Strong buy 1
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $8.00High $22.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.01 vs $-0.06
Surprise
+83.33%

OCGN news

All OCGN news

Ocugen peers

Health Care sector
OCGN peer companies
CompanyPrice% ChgMarket capCompare
EIKNEikon Therapeutics Inc.4.74-0.42%$256.84Mvs OCGN
SABSSAB Biotherapeutics Inc.2.81-3.44%$253.15Mvs OCGN
EDITEditas Medicine Inc.1.64-4.09%$253.12Mvs OCGN
AGMBAgomAb Therapeutics NV ADR5.45-3.02%$268.40Mvs OCGN
KYTXKyverna Therapeutics Inc.4.26-2.52%$269.33Mvs OCGN
AGENAgenus Inc.5.97-2.77%$270.12Mvs OCGN
LXEOLexeo Therapeutics Inc.2.96+0.34%$245.05Mvs OCGN
PLXProtalix BioTherapeutics Inc. (DE)2.90-5.23%$244.52Mvs OCGN

Indexes, lists and sector

Ocugen stock FAQ

What is Ocugen's stock price today?

OCGN last traded at $0.7679 as of Nov 20, 4:00 PM EST, up 4.79% on the day. Prices are delayed at least 15 minutes.

Does Ocugen pay a dividend?

No. Ocugen does not currently pay a regular cash dividend.

Who is Ocugen's CEO?

Dr. Shankar Musunuri M.B.A., Ph.D. is the chief executive officer of Ocugen Inc., which has about 116 employees.

Has OCGN ever split its stock?

Yes. The most recent OCGN stock split was a 1-for-60 split on Sep 30, 2019.

What is the OCGN 52-week high?

The 52-week high for OCGN is $2.73 and the 52-week low is $0.691. The stock is currently 71.8% below its high.

Compare OCGN